Germany: Basic patents and supplementary protection certificates

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: Basic patents and supplementary protection certificates

In recent ex-parte appeal proceedings (decision 14 W (pat) 10/16 of January 23 2018), the German Federal Patent Court (GFPC) contributed to the interpretation of Article 3(a) of Regulation (EC) No 469/2009 (the Regulation).

The appellant based the request to obtain a Supplementary Protection Certificate (SPC) for the product – a hexavalent combination vaccine containing previously known antigens in a formulation with special adjuvants – on the corresponding market authorisations and the German part of granted European patent EP 0 835 663 B1 (the basic patent in the sense of Article 3(a) of the Regulation).

The German Patent and Trademark Office (GPTO) rejected the request and pointed out that the vaccine composition is not protected by the basic patent. The requirement of Article 3(a) of the Regulation is not fulfilled, and, therefore, an SPC cannot be granted. According to the CJEU decisions Actavis/Sanofi (C-443/12), Georgetown II (C-484/12) and Actavis/Boehringer (C-577/13), a product can only be regarded as being protected by a basic patent if the active ingredient or combination of active ingredients is protected as such. The product in question must represent the central inventive concept of the subject matter claimed in the basic patent. In the present case, however, the central inventive concept was seen in the use of the special adjuvants in the preparation of the combination vaccine, but not in the combination vaccine composition itself. Therefore, the vaccine composition is not protected, the GPTO argued.

The GFPC did not agree and granted the SPC. The Court emphasised that in the present case the principles defined in the CJEU's decisions Medeva (C-322/10) and Eli Lilly (C-493/12) for the assessment of whether a product can be regarded as being protected by the basic patent are fulfilled. Furthermore, decisions Actavis/Sanofi, Georgetown II and Actavis/Boehringer do not contain criteria extending beyond the principles defined in Medeva and Eli Lilly. Instead, these decisions primarily relate to the requirement of Article 3(c) of the Regulation, i.e. the assessment of whether the product has not already been the subject of an SPC.

It remains to be seen whether the CJEU will comment on the GFPC's view when ruling on aspects of the interpretation of Article 3(a) of the Regulation in the future. The GFPC and the English Patents Court recently directed referrals to the CJEU concerning the interpretation of Article 3(a) of the Regulation.

Klaus Breitenstein


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

Ed White at Clarivate provides an exclusive insight into the innovation power clusters reshaping Europe and the Middle East’s IP landscape, and why quality is the new currency of invention
In the first in a new podcast series celebrating the tenth anniversary of IP Inclusive, we look back at the network’s origins and discuss its mission
Rebecca Schwarz at Haynes Boone shares how her team secured victory for biopharma client RedHill in a licensing dispute involving a developmental cancer drug
News of a breakaway firm launching in Germany and a spike in vaccine-related patent applications were also among the top talking points
A flurry of hiring activity among UK firms suggests they are confident of mounting a serious challenge at the UPC
With the submission deadline approaching, we sat down with our research team to provide top tips on how to make your firm stand out
EA, owner of video games including Madden and The Sims, will be sold to a consortium including Saudi Arabia’s Public Investment Fund and a firm owned by Donald Trump’s son-in-law
New arrival marks Mewburn Ellis' second partner hire in ten days as firm looks to boost patent litigation and prosecution capabilities
In-house counsel and teams are invited to submit information for the 21st annual Managing IP Awards
The 2025 list of Rising Stars and Corporate Stars, produced by Managing IP’s accreditation title IP STARS, is now available
Gift this article